Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts

Although approximately half of all metastatic colorectal cancers (mCRCs) harbour mutations in KRAS or NRAS, hardly any progress has been made regarding targeted treatment for this group over the last few years. Here, we investigated the efficacy of vertical inhibition of the RAS‐pathway by targeting...

Full description

Bibliographic Details
Main Authors: Timm M. Reissig, Swetlana Ladigan‐Badura, Anja Steinberg, Abdelouahid Maghnouj, Ting Li, Berlinda Verdoodt, Sven T. Liffers, Michael Pohl, Heiner Wolters, Christian Teschendorf, Richard Viebahn, Jakob Admard, Nicolas Casadei, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Deepak B. Vangala
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Molecular Oncology
Subjects:
CRC
EGFR
MEK
PDX
resistance
targeted therapy
Online Access:https://doi.org/10.1002/1878-0261.13510

Internet

https://doi.org/10.1002/1878-0261.13510

Similar Items